High-dose dazucorilant showed significant survival benefit in a Phase 2 ALS trial. It reduced mortality risk by up to 87% over two years for ALS patients. A pivotal Phase 3 trial for this ALS therapy ...
An Annapolis man has planned a cross-country bike ride to fundraise for research into his wife’s terminal illness. When Laura ...
Clinical Trials Arena on MSN
Corcept’s ALS drug demonstrates two-year benefit despite primary endpoint miss
After two years of treatment, there was an 87% reduction in death in treated patients compared with those who received ...
Gear-obsessed editors choose every product we review. We may earn commission if you buy from a link. Why Trust Us? Here’s what you’ll learn when you read this story: While bones can regrow themselves ...
Stacker looked at the #1 rock songs of the 1970s using the Billboard Hot 100 and MusicBrainz, an open music encyclopedia via ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results